MLLCF (Molecular Partners AG) Total Stockholders Equity: $86.95 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MLLCF Molecular Partners AG MLLCF
25 GF Score
Price $3.80
GF Value $0.44
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Molecular Partners AG Total Stockholders Equity?

Molecular Partners AG MLLCF 25 Total Stockholders Equity is $86.95 Mil as of Mar. 2026. GuruFocus rates MLLCF with a GF Score™ of 25/100 and a GF Value™ of $0.44 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Molecular Partners AG's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $86.95 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Molecular Partners AG's Book Value per Share for the quarter that ended in Mar. 2026 was $2.32. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Molecular Partners AG's Debt-to-Equity for the quarter that ended in Mar. 2026 was 0.05.

Molecular Partners AG  (OTCPK:MLLCF) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Molecular Partners AG's Book Value per Share for the quarter that ended in Mar. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(86.945-0)/37.511
=2.32

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Molecular Partners AG's Debt-to-Equity for the quarter that ended in Mar. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(1.534 + 2.713) / 86.945
=0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Molecular Partners AG Total Stockholders Equity Related Terms

Molecular Partners AG Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Molecular Partners AG's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Molecular Partners AG Total Stockholders Equity Chart

Molecular Partners AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 116.49 252.43 204.01 158.86 100.81

Molecular Partners AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 145.08 131.16 120.00 100.81 86.95
MLLCF
25GF Score
Molecular Partners AG MLLCF
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of $86.95 Mil mean?
Molecular Partners AG (MLLCF) has a Total Stockholders Equity of $86.95 Mil as of Mar. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Molecular Partners AG and its competitors.
Is Molecular Partners AG's Total Stockholders Equity too high?
Molecular Partners AG's current Total Stockholders Equity is $86.95 Mil. Overall, Molecular Partners AG has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Molecular Partners AG's Total Stockholders Equity compare to VRTX and REGN?
Molecular Partners AG's Total Stockholders Equity of $86.95 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Molecular Partners AG and its competitors. Molecular Partners AG's current Total Stockholders Equity is $86.95 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Molecular Partners AG stock overvalued right now?
Based on GuruFocus' analysis, Molecular Partners AG (MLLCF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.44, compared to a current price of $3.80 — trading 763.6% above its estimated fair value. The current Total Stockholders Equity is $86.95 Mil. Molecular Partners AG's overall GF Score™ is 25/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Molecular Partners AG (MLLCF), the current Total Stockholders Equity is $86.95 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Molecular Partners AG (MLLCF) Overvalued in 2026?

Based on GuruFocus' analysis, Molecular Partners AG stock appears to be overvalued. The current stock price of $3.80 is trading 763.6% above its estimated GF Value™ of $0.44. GuruFocus considers Molecular Partners AG to be Significantly Overvalued.

Key valuation signals for MLLCF:

  • Total Stockholders Equity: $86.95 Mil
  • GF Value™: $0.44 vs. price of $3.80 (763.6% above fair value)
  • GF Score™: 25/100 with 3 warning signs

No single metric tells the full story. See the MLLCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Molecular Partners AG Business Description

Address Wagistrasse 14, Schlieren, Zurich, CHE, 8952
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
25GF Score

Get the complete analysis for MLLCF

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.80
Price
$0.44
GF Value